Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Meiosis I01:49

Meiosis I

Meiosis is a carefully orchestrated set of cell divisions, the goal of which—in humans—is to produce haploid sperm or eggs, each containing half the number of chromosomes present in somatic cells elsewhere in the body. Meiosis I is the first such division, and involves several key steps, among them: condensation of replicated chromosomes in diploid cells; the pairing of homologous chromosomes and their exchange of information; and finally, the separation of homologous chromosomes by a...
Disorders of Leukocytes01:27

Disorders of Leukocytes

Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...
Meiosis vs. Mitosis02:57

Meiosis vs. Mitosis

Cell division is necessary for growth and reproduction in organisms. Mitosis aids cell growth and development by dividing somatic cells. In contrast, meiosis causes the division of germ cells and plays an essential role in sexual reproduction. Due to their unique functional requirements, mitosis and meiosis differ from each other in multiple aspects.
Before the start of mitosis and meiosis I, the cell synthesizes DNA, resulting in two homologous copies of each chromosome. DNA synthesis is...
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
Karyotyping01:17

Karyotyping

Overview
Nondisjunction01:29

Nondisjunction

During meiosis, chromosomes occasionally separate improperly. This occurs due to failure of homologous chromosome separation during meiosis I or failed sister chromatid separation during meiosis II. In some species, notably plants, nondisjunction can result in an organism with an entire additional set of chromosomes, which is called polyploidy. In humans, nondisjunction can occur during male or female gametogenesis and the resulting gametes possess one too many or one too few chromosomes.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Escalating diabetes prevalence in pakistan: a qualitative study of endocrinologists' perspectives on contributing factors, management barriers, and strategies.

BMC endocrine disorders·2026
Same author

NCCN Guidelines® Insights: Myeloproliferative Neoplasms, Version 2.2026.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Trait prioritization and genotype selection for heat stress tolerance in wheat <i>via</i> structural equation modeling and principal component analysis (PCA).

PeerJ·2026
Same author

Pharmacological inhibition of sclerostin protects bone from B-cell acute lymphoblastic leukemia-mediated destruction.

HemaSphere·2026
Same author

PTP4A2 promotes leukemogenesis through inhibiting the p53 tumor suppressor signaling pathway in leukemia-initiating cells.

Blood advances·2026
Same author

RPS19 and RPL5 haploinsufficient models reveal divergent ribosomal subunit controls of fetal hematopoiesis.

Nature communications·2026

Related Experiment Video

Updated: May 26, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

Myeloid leukemia in Down syndrome.

Irum Khan1, Sébastien Malinge, John Crispino

  • 1Division of Hematology/Oncology, Northwestern University, Chicago, Illinois 60611, USA.

Critical Reviews in Oncogenesis
|December 14, 2011
PubMed
Summary

Children with Down syndrome (DS) have a higher risk of leukemia, particularly acute megakaryoblastic leukemia (AMKL). Understanding genetic factors like GATA1 mutations and trisomy 21 is crucial for developing effective treatments.

More Related Videos

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia
06:33

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia

Published on: November 10, 2023

Related Experiment Videos

Last Updated: May 26, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia
06:33

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia

Published on: November 10, 2023

Area of Science:

  • Hematology
  • Genetics
  • Pediatric Oncology

Background:

  • Adults with Down syndrome (DS) have lower cancer rates, but children with DS face increased leukemia risk.
  • Acute megakaryoblastic leukemia (AMKL), a rare subtype of acute myeloid leukemia (AML), accounts for nearly half of childhood leukemias in DS patients.

Purpose of the Study:

  • To summarize clinical features of myeloid leukemia in Down syndrome.
  • To review recent research on leukemogenesis mechanisms in DS, focusing on GATA1 mutations and trisomy 21.
  • To discuss current and future treatment strategies for DS-related leukemia.

Main Methods:

  • Literature review of clinical features, genetic mechanisms, and treatment strategies for myeloid leukemia in Down syndrome.
  • Analysis of recent research on GATA1 mutations and trisomy 21 in leukemogenesis.
  • Synthesis of information to provide a comprehensive overview.

Main Results:

  • Children with Down syndrome have a significantly increased risk of developing acute megakaryoblastic leukemia (AMKL).
  • GATA1 mutations and the presence of trisomy 21 are key factors in the development of DS-AMKL.
  • Trisomy 21 plays a role in various hematologic malignancies, making DS-AMKL a relevant model.

Conclusions:

  • Further understanding of chromosome 21 gene contributions to DS-AMKL can advance knowledge of broader leukemia patient populations.
  • Targeting specific genetic pathways, including those affected by trisomy 21, holds promise for improved therapeutic interventions.
  • Continued research into the unique aspects of leukemia in Down syndrome is essential for advancing pediatric cancer treatment.